Compare EAF & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EAF | LCTX |
|---|---|---|
| Founded | 1886 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.3M | 251.4M |
| IPO Year | 2018 | 1996 |
| Metric | EAF | LCTX |
|---|---|---|
| Price | $12.14 | $1.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $9.00 | $5.50 |
| AVG Volume (30 Days) | 582.1K | ★ 1.4M |
| Earning Date | 10-23-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | $14,556,000.00 |
| Revenue This Year | $2.85 | $4.38 |
| Revenue Next Year | $20.35 | $10.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $4.92 | $0.88 |
| 52 Week High | $19.72 | $2.09 |
| Indicator | EAF | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.56 | 56.46 |
| Support Level | $5.79 | $1.02 |
| Resistance Level | $19.72 | $1.05 |
| Average True Range (ATR) | 0.87 | 0.06 |
| MACD | 0.43 | 0.01 |
| Stochastic Oscillator | 99.05 | 96.66 |
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.